PRIMARY STUDY

Micronized Palmitoylethanolamide-Polydatin Reduces the Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome

Key Findings:  In this study micronized-palmitoylethanolamide-polydatin (m-PEA-Pol) was effective in reducing pain and urinary frequency associated with treatment-resistant cystitis and bladder pain syndromes. It had a less than significant increase in bladder capacity

Type of Study:  Clinical Trial

Study Sample Size:  32

Study Result:  Positive

Study Location(s):  Italy

Year of Pub:  2019


Cannabinoids Studied:  Palmitoylethanolamide (PEA)

Phytocannabinoid Source:  Not Applicable

Receptors Studied:  GPCR 55, TRPV1, PPARs

DOSING DETAILS   

Study Dosing Objective:  Effective Dose

Established Protocol:  Effective dose

Route of Administration:  Oral (Ingestion)

Dosing Regimen:  400 mg m-PEA plus 40 mg polydatin

Adverse Events:  None of the participants reported adverse events



Link to study